---
document_datetime: 2025-12-09 23:27:20
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/krazati.html
document_name: krazati.html
version: success
processing_time: 0.122031
conversion_datetime: 2025-12-24 01:23:23.754395
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Krazati

[RSS](/en/individual-human-medicine.xml/67692)

##### Authorised

This medicine is authorised for use in the European Union

adagrasib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Krazati](#news-on)
- [More information on Krazati](#more-information-on-krazati-63251)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Krazati is a medicine for treating adults with advanced non-small cell lung cancer (NSCLC) when the cancer cells have a particular genetic change (mutation) known as KRAS G12C. It is used in patients whose disease got worse after at least one systemic treatment (a treatment given by injection or by mouth and affecting the whole body).

Krazati contains the active substance adagrasib.

Expand section

Collapse section

## How is Krazati used?

The medicine can only be obtained with a prescription and should be started by a doctor experienced in the use of cancer medicines.

Krazati is available as tablets to be taken twice a day. Treatment should continue until the disease gets worse or until the side effects become unmanageable. The doctor may delay or reduce the dose, or stop treatment, if certain side effects occur. Before starting treatment with Krazati, the presence of the *KRAS* G12C mutation must be confirmed by an appropriate test.

For more information about using Krazati, see the package leaflet or contact your doctor or pharmacist.

## How does Krazati work?

Genetic changes to the KRAS gene can produce an altered form of the KRAS protein, which causes the uncontrolled growth of cancer cells. The active substance in Krazati, adagrasib, attaches to the altered protein inside cancer cells, stopping the protein from functioning and thereby slowing the growth and spread of the cells. It also encourages processes that kill the cancer cells.

## What benefits of Krazati have been shown in studies?

Krazati was investigated in a main study involving 116 adults with advanced NSCLC with a KRAS G12C mutation whose disease got worse after previously being treated with other cancer medicines; Krazati was not compared with any other medicine or placebo (a dummy treatment). Overall, 41.4% of patients (48 out of 116) in the study responded partially or completely to treatment with Krazati (as measured by shrinkage in the size of the cancer). On average, the response lasted for 8.5 months.

## What are the risks associated with Krazati?

For the full list of side effects and restrictions with Krazati, see the package leaflet.

The most common side effects with Krazati (which may affect more than 1 in 5 people) include diarrhoea, nausea (feeling sick), vomiting, tiredness, anaemia (low levels of red blood cells), increased blood levels of creatinine or liver enzymes (a sign of possible liver problems), decreased appetite, peripheral oedema (swelling especially of the ankles and feet), dizziness and hyponatraemia (low blood sodium levels).

Krazati must not be used together with certain medicines known as 'CYP3A substrates with a narrow therapeutic index' (alfuzosin, amiodarone, cisapride, pimozide, quinidine, ergotamine, dihydroergotamine, quetiapine, lovastatin, simvastatin, sildenafil, sirolimus, midazolam, triazolam, ticagrelor and tacrolimus), as this may increase the risk of serious and life-threatening side effects.

## Why is Krazati authorised in the EU?

Krazati was shown to be of benefit for patients with NSCLC with a *KRAS* G12C mutation and to have an acceptable safety profile. Although the main study did not compare Krazati with another cancer treatment, it showed that the medicine was effective at treating the cancer including in patients whose disease got worse after several different treatments.

Krazati has been given 'conditional authorisation'. This means that the European Medicines Agency decided that the benefits of Krazati are greater than its risks, but the company will have to provide additional evidence after authorisation.

Conditional authorisation is granted on the basis of less comprehensive data than are normally required. It is granted for medicines that fulfil an unmet medical need to treat serious diseases and when the benefits of having them available earlier outweigh any risks associated with using the medicines while waiting for further evidence. Every year, the Agency will review any new information that becomes available until data become comprehensive and this overview will be updated as necessary.

Since Krazati was given conditional authorisation, at the time of approval the company was required to provide the final results of an ongoing study comparing Krazati with docetaxel (another cancer medicine) in patients with NSCLC with a *KRAS* G12C mutation who have received at least one prior treatment.

## What measures are being taken to ensure the safe and effective use of Krazati?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Krazati have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Krazati are continuously monitored. Suspected side effects reported with Krazati are carefully evaluated and any necessary action taken to protect patients.

## Other information about Krazati

Krazati received a conditional marketing authorisation valid throughout the EU on 5 January 2024.

Krazati : EPAR - Medicine overview

Reference Number: EMA/530345/2023

English (EN) (123.11 KB - PDF)

**First published:** 13/03/2024

[View](/en/documents/overview/krazati-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-942)

български (BG) (149 KB - PDF)

**First published:**

13/03/2024

[View](/bg/documents/overview/krazati-epar-medicine-overview_bg.pdf)

español (ES) (122.6 KB - PDF)

**First published:**

13/03/2024

[View](/es/documents/overview/krazati-epar-medicine-overview_es.pdf)

čeština (CS) (145.65 KB - PDF)

**First published:**

13/03/2024

[View](/cs/documents/overview/krazati-epar-medicine-overview_cs.pdf)

dansk (DA) (122.22 KB - PDF)

**First published:**

13/03/2024

[View](/da/documents/overview/krazati-epar-medicine-overview_da.pdf)

Deutsch (DE) (125.7 KB - PDF)

**First published:**

13/03/2024

[View](/de/documents/overview/krazati-epar-medicine-overview_de.pdf)

eesti keel (ET) (118.98 KB - PDF)

**First published:**

13/03/2024

[View](/et/documents/overview/krazati-epar-medicine-overview_et.pdf)

ελληνικά (EL) (153.53 KB - PDF)

**First published:**

13/03/2024

[View](/el/documents/overview/krazati-epar-medicine-overview_el.pdf)

français (FR) (124.41 KB - PDF)

**First published:**

13/03/2024

[View](/fr/documents/overview/krazati-epar-medicine-overview_fr.pdf)

hrvatski (HR) (143.79 KB - PDF)

**First published:**

13/03/2024

[View](/hr/documents/overview/krazati-epar-medicine-overview_hr.pdf)

italiano (IT) (121.95 KB - PDF)

**First published:**

13/03/2024

[View](/it/documents/overview/krazati-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (153.43 KB - PDF)

**First published:**

13/03/2024

[View](/lv/documents/overview/krazati-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (143.83 KB - PDF)

**First published:**

13/03/2024

[View](/lt/documents/overview/krazati-epar-medicine-overview_lt.pdf)

magyar (HU) (145.86 KB - PDF)

**First published:**

13/03/2024

[View](/hu/documents/overview/krazati-epar-medicine-overview_hu.pdf)

Malti (MT) (148.05 KB - PDF)

**First published:**

13/03/2024

[View](/mt/documents/overview/krazati-epar-medicine-overview_mt.pdf)

Nederlands (NL) (122.62 KB - PDF)

**First published:**

13/03/2024

[View](/nl/documents/overview/krazati-epar-medicine-overview_nl.pdf)

polski (PL) (145.95 KB - PDF)

**First published:**

13/03/2024

[View](/pl/documents/overview/krazati-epar-medicine-overview_pl.pdf)

português (PT) (123.44 KB - PDF)

**First published:**

13/03/2024

[View](/pt/documents/overview/krazati-epar-medicine-overview_pt.pdf)

română (RO) (143.23 KB - PDF)

**First published:**

13/03/2024

[View](/ro/documents/overview/krazati-epar-medicine-overview_ro.pdf)

slovenčina (SK) (145.41 KB - PDF)

**First published:**

13/03/2024

[View](/sk/documents/overview/krazati-epar-medicine-overview_sk.pdf)

slovenščina (SL) (142.62 KB - PDF)

**First published:**

13/03/2024

[View](/sl/documents/overview/krazati-epar-medicine-overview_sl.pdf)

Suomi (FI) (120.09 KB - PDF)

**First published:**

13/03/2024

[View](/fi/documents/overview/krazati-epar-medicine-overview_fi.pdf)

svenska (SV) (120.47 KB - PDF)

**First published:**

13/03/2024

[View](/sv/documents/overview/krazati-epar-medicine-overview_sv.pdf)

Krazati : EPAR - Risk management plan

English (EN) (3.9 MB - PDF)

**First published:** 13/03/2024

**Last updated:** 02/12/2025

[View](/en/documents/rmp/krazati-epar-risk-management-plan_en.pdf)

## Product information

Krazati : EPAR - Product information

English (EN) (446.44 KB - PDF)

**First published:** 22/05/2024

**Last updated:** 02/12/2025

[View](/en/documents/product-information/krazati-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-279)

български (BG) (438.75 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/bg/documents/product-information/krazati-epar-product-information_bg.pdf)

español (ES) (447.26 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/es/documents/product-information/krazati-epar-product-information_es.pdf)

čeština (CS) (439.47 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/cs/documents/product-information/krazati-epar-product-information_cs.pdf)

dansk (DA) (326.38 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/da/documents/product-information/krazati-epar-product-information_da.pdf)

Deutsch (DE) (463.66 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/de/documents/product-information/krazati-epar-product-information_de.pdf)

eesti keel (ET) (421.31 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/et/documents/product-information/krazati-epar-product-information_et.pdf)

ελληνικά (EL) (435.16 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/el/documents/product-information/krazati-epar-product-information_el.pdf)

français (FR) (329.26 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/fr/documents/product-information/krazati-epar-product-information_fr.pdf)

hrvatski (HR) (397.43 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/hr/documents/product-information/krazati-epar-product-information_hr.pdf)

íslenska (IS) (317.41 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/is/documents/product-information/krazati-epar-product-information_is.pdf)

italiano (IT) (446.39 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/it/documents/product-information/krazati-epar-product-information_it.pdf)

latviešu valoda (LV) (404.76 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/lv/documents/product-information/krazati-epar-product-information_lv.pdf)

lietuvių kalba (LT) (400.56 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/lt/documents/product-information/krazati-epar-product-information_lt.pdf)

magyar (HU) (504.86 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/hu/documents/product-information/krazati-epar-product-information_hu.pdf)

Malti (MT) (347.19 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/mt/documents/product-information/krazati-epar-product-information_mt.pdf)

Nederlands (NL) (323.5 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/nl/documents/product-information/krazati-epar-product-information_nl.pdf)

norsk (NO) (315.53 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/no/documents/product-information/krazati-epar-product-information_no.pdf)

polski (PL) (465.42 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/pl/documents/product-information/krazati-epar-product-information_pl.pdf)

português (PT) (321.2 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/pt/documents/product-information/krazati-epar-product-information_pt.pdf)

română (RO) (411.27 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/ro/documents/product-information/krazati-epar-product-information_ro.pdf)

slovenčina (SK) (409.54 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/sk/documents/product-information/krazati-epar-product-information_sk.pdf)

slovenščina (SL) (405.08 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/sl/documents/product-information/krazati-epar-product-information_sl.pdf)

Suomi (FI) (404.74 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/fi/documents/product-information/krazati-epar-product-information_fi.pdf)

svenska (SV) (269.78 KB - PDF)

**First published:**

22/05/2024

**Last updated:**

02/12/2025

[View](/sv/documents/product-information/krazati-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0010/G 17/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Krazati : EPAR - All authorised presentations

English (EN) (36.64 KB - PDF)

**First published:** 13/03/2024

[View](/en/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-709)

български (BG) (45.86 KB - PDF)

**First published:**

13/03/2024

[View](/bg/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.98 KB - PDF)

**First published:**

13/03/2024

[View](/es/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_es.pdf)

čeština (CS) (51.69 KB - PDF)

**First published:**

13/03/2024

[View](/cs/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (40.81 KB - PDF)

**First published:**

13/03/2024

[View](/da/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (37.95 KB - PDF)

**First published:**

13/03/2024

[View](/de/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (38.52 KB - PDF)

**First published:**

13/03/2024

[View](/et/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (53.06 KB - PDF)

**First published:**

13/03/2024

[View](/el/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_el.pdf)

français (FR) (37.98 KB - PDF)

**First published:**

13/03/2024

[View](/fr/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (73.75 KB - PDF)

**First published:**

13/03/2024

[View](/hr/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (37.58 KB - PDF)

**First published:**

13/03/2024

[View](/is/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_is.pdf)

italiano (IT) (37.66 KB - PDF)

**First published:**

13/03/2024

[View](/it/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (47.8 KB - PDF)

**First published:**

13/03/2024

[View](/lv/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (57.39 KB - PDF)

**First published:**

13/03/2024

[View](/lt/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (52.64 KB - PDF)

**First published:**

13/03/2024

[View](/hu/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.49 KB - PDF)

**First published:**

13/03/2024

[View](/mt/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (35.83 KB - PDF)

**First published:**

13/03/2024

[View](/nl/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (39.86 KB - PDF)

**First published:**

13/03/2024

[View](/no/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_no.pdf)

polski (PL) (66.24 KB - PDF)

**First published:**

13/03/2024

[View](/pl/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_pl.pdf)

português (PT) (40.25 KB - PDF)

**First published:**

13/03/2024

[View](/pt/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_pt.pdf)

română (RO) (50.65 KB - PDF)

**First published:**

13/03/2024

[View](/ro/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (53.05 KB - PDF)

**First published:**

13/03/2024

[View](/sk/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (53.56 KB - PDF)

**First published:**

13/03/2024

[View](/sl/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (36.48 KB - PDF)

**First published:**

13/03/2024

[View](/fi/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (35.72 KB - PDF)

**First published:**

13/03/2024

[View](/sv/documents/all-authorised-presentations/krazati-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Krazati Active substance adagrasib International non-proprietary name (INN) or common name adagrasib Therapeutic area (MeSH) Carcinoma, Non-Small-Cell Lung Anatomical therapeutic chemical (ATC) code L01XX77

### Pharmacotherapeutic group

Other antineoplastic agents

### Therapeutic indication

Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.

## Authorisation details

EMA product number EMEA/H/C/006013

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

Bristol-Myers Squibb Pharma EEIG

Plaza 254

Opinion adopted 09/11/2023 Marketing authorisation issued 05/01/2024 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Krazati : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (156.8 KB - PDF)

**First published:** 22/05/2024

**Last updated:** 02/12/2025

[View](/en/documents/procedural-steps-after/krazati-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Krazati : EPAR - Public assessment report

Adopted

Reference Number: EMA/552099/2023

English (EN) (6.47 MB - PDF)

**First published:** 13/03/2024

[View](/en/documents/assessment-report/krazati-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Krazati

Adopted

Reference Number: EMA/492226/2023

English (EN) (130.73 KB - PDF)

**First published:** 10/11/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-krazati_en.pdf)

#### News on Krazati

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-6-9-november-2023) 10/11/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

#### More information on Krazati

Questions and answers on the approval of the marketing authorisation for Krazati (adagrasib) - outcome of re-examination

Reference Number: EMA/497823/2023

English (EN) (105.44 KB - PDF)

**First published:** 10/11/2023

[View](/en/documents/smop-initial/questions-and-answers-approval-marketing-authorisation-krazati-adagrasib-outcome-re-examination_en.pdf)

**This page was last updated on** 02/12/2025

## Share this page

[Back to top](#main-content)